Which class of medications is often preferred for patients with type 2 diabetes who also have chronic kidney disease?

SGLT-2 inhibitors are often the preferred class of medications for patients with type 2 diabetes who also have chronic kidney disease (CKD) due to their unique benefits beyond glycemic control. These medications work by promoting the excretion of glucose through the urine, which not only aids in lowering blood glucose levels but also has renal protective effects. In particular, SGLT-2 inhibitors have been shown to slow the progression of kidney disease and reduce the risk of cardiovascular events in patients with concomitant CKD.

For individuals with type 2 diabetes, managing blood sugar levels is crucial, but protecting renal function and minimizing cardiovascular risk are equally important, especially in those with pre-existing kidney issues. The evidence supporting the renal benefits of SGLT-2 inhibitors in patients with type 2 diabetes and CKD is robust, making them a preferred option in this population.

While DPP-4 inhibitors and GLP-1 receptor agonists also provide some benefits and can be used in patients with kidney disease, they do not offer the same degree of renal protection as SGLT-2 inhibitors. Metformin, although a first-line treatment for type 2 diabetes, is typically contraindicated in patients with significantly impaired renal function due to the risk